MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 12, Pages 4544
Publisher
MDPI AG
Online
2020-06-26
DOI
10.3390/ijms21124544
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- miRNAs as Key Players in the Management of Cutaneous Melanoma
- (2020) Celeste Lorusso et al. Cells
- The Circulating Transcriptome as a Source of Biomarkers for Melanoma
- (2019) Carla Solé et al. Cancers
- Role of miRNAs in Melanoma Metastasis
- (2019) Anna Gajos-Michniewicz et al. Cancers
- MicroRNA-155 expression is enhanced by T-cell receptor stimulation strength and correlates with improved tumor control in melanoma
- (2019) Amaia Martinez-Usatorre et al. Cancer Immunology Research
- Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies
- (2019) Stephen A. Luebker et al. Frontiers in Oncology
- miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A
- (2019) Simona Caporali et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Understanding the Modus Operandi of MicroRNA Regulatory Clusters
- (2019) Arthur C. Oliveira et al. Cells
- Development and validation of a plasma-based melanoma biomarker suitable for clinical use
- (2018) Ryan Van Laar et al. BRITISH JOURNAL OF CANCER
- Emerging Roles of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Immunological Disorders and Cancer
- (2018) et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells
- (2018) Federica Fratangelo et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Serum exosomal microRNAs as potent circulating biomarkers for melanoma
- (2018) Li Tengda et al. MELANOMA RESEARCH
- miR-550a-3-5p acts as a tumor suppressor and reverses BRAF inhibitor resistance through the direct targeting of YAP
- (2018) Min Ho Choe et al. Cell Death & Disease
- Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma
- (2018) Luigi Fattore et al. CELL DEATH AND DIFFERENTIATION
- NKG2D Ligands–Critical Targets for Cancer Immune Escape and Therapy
- (2018) Dominik Schmiedel et al. Frontiers in Immunology
- Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation
- (2018) Jacob O'Brien et al. Frontiers in Endocrinology
- The Network of Non-coding RNAs in Cancer Drug Resistance
- (2018) Fabio Corrà et al. Frontiers in Oncology
- Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma
- (2018) Veronica Huber et al. JOURNAL OF CLINICAL INVESTIGATION
- Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma
- (2018) Fernanda Costa Svedman et al. PLoS One
- KEYNOTE-006: a success in melanoma, but a long way to go
- (2017) Kilian Wistuba-Hamprecht et al. LANCET
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway
- (2017) Lisa Koetz-Ploch et al. Pigment Cell & Melanoma Research
- BRAFV600inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells
- (2017) Taral R. Lunavat et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p
- (2017) Valentina Audrito et al. Oncotarget
- Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF
- (2017) Jae-Hyeon Kim et al. Cancer Research and Treatment
- MiR-146 and miR-125 in the regulation of innate immunity and inflammation
- (2016) Hye-Mi Lee et al. BMB Reports
- Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies
- (2016) Min Hwan Kim et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- miRNAs in Melanoma: Tumor Suppressors and Oncogenes with Prognostic Potential
- (2016) Michal Wozniak et al. CURRENT MEDICINAL CHEMISTRY
- MicroRNAs as potential diagnostic and prognostic biomarkers in melanoma
- (2016) Hamed Mirzaei et al. EUROPEAN JOURNAL OF CANCER
- Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs
- (2016) Kathy A. Gelato et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- MicroRNAs role as potential biomarkers and key regulators in melanoma
- (2016) Chiara Varamo et al. GENES CHROMOSOMES & CANCER
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- (2016) F Stephen Hodi et al. LANCET ONCOLOGY
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Pairing beyond the Seed Supports MicroRNA Targeting Specificity
- (2016) James P. Broughton et al. MOLECULAR CELL
- Melanoma miRNA trafficking controls tumour primary niche formation
- (2016) Shani Dror et al. NATURE CELL BIOLOGY
- The genomic landscape of cutaneous melanoma
- (2016) Tongwu Zhang et al. Pigment Cell & Melanoma Research
- miR-579-3p controls melanoma progression and resistance to target therapy
- (2016) Luigi Fattore et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Intracellular and extracellular microRNA: An update on localization and biological role
- (2016) Julia A. Makarova et al. PROGRESS IN HISTOCHEMISTRY AND CYTOCHEMISTRY
- miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways
- (2016) Xiaoyan Sun et al. Oncotarget
- miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion
- (2016) Qing Li et al. Oncotarget
- Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction
- (2015) Gatien Moriceau et al. CANCER CELL
- Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation
- (2015) M. H. Kim et al. EMBO JOURNAL
- miRNAs in melanoma: a defined role in tumor progression and metastasis
- (2015) Francesco Mannavola et al. Expert Review of Clinical Immunology
- What’s new in melanoma? Combination!
- (2015) Paolo A Ascierto et al. Journal of Translational Medicine
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment
- (2015) Shujing Liu et al. Pigment Cell & Melanoma Research
- Small RNA deep sequencing discriminates subsets of extracellular vesicles released by melanoma cells – Evidence of unique microRNA cargos
- (2015) Taral R Lunavat et al. RNA Biology
- Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b
- (2015) Elisabetta Vergani et al. Oncotarget
- A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme
- (2015) Gilli Galore-Haskel et al. Oncotarget
- miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma
- (2015) Mitchell S. Stark et al. Oncotarget
- Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets
- (2015) Giuseppe Palmieri et al. Frontiers in Oncology
- Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
- (2015) Francesco Spagnolo et al. Oncotarget
- miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2
- (2015) Szu-Mam Liu et al. Oncotarget
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013
- (2014) Paolo A Ascierto et al. Journal of Translational Medicine
- The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
- (2014) V. Yadav et al. MOLECULAR CANCER THERAPEUTICS
- Regulation of microRNA biogenesis
- (2014) Minju Ha et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- MicroRNAs in cancer: biomarkers, functions and therapy
- (2014) Josie Hayes et al. TRENDS IN MOLECULAR MEDICINE
- Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
- (2014) Georgina V. Long et al. Nature Communications
- miR-125a-5p Regulates Differential Activation of Macrophages and Inflammation
- (2013) Sami Banerjee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- MicroRNAs and other non-coding RNAs as targets for anticancer drug development
- (2013) Hui Ling et al. NATURE REVIEWS DRUG DISCOVERY
- miR in melanoma development: miRNAs and acquired hallmarks of cancer in melanoma
- (2013) Paige E. Bennett et al. PHYSIOLOGICAL GENOMICS
- Next-generation sequencing of microRNAs uncovers expression signatures in polarized macrophages
- (2013) Viviana Cobos Jiménez et al. PHYSIOLOGICAL GENOMICS
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- (2013) H. Shi et al. Cancer Discovery
- MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
- (2013) N. Wagle et al. Cancer Discovery
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- (2013) E. M. Van Allen et al. Cancer Discovery
- miR-200c Inhibits Melanoma Progression and Drug Resistance through Down-Regulation of Bmi-1
- (2012) Shujing Liu et al. AMERICAN JOURNAL OF PATHOLOGY
- Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma
- (2012) J. S. Khalili et al. CLINICAL CANCER RESEARCH
- The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
- (2012) X. Jiang et al. CLINICAL CANCER RESEARCH
- The role of BRAF V600 mutation in melanoma
- (2012) Paolo A Ascierto et al. Journal of Translational Medicine
- Oncogenic B-Raf signaling in melanoma cells controls a network of microRNAs with combinatorial functions
- (2012) K L Couts et al. ONCOGENE
- Tumor Suppressive MicroRNAs miR-34a/c Control Cancer Cell Expression of ULBP2, a Stress-Induced Ligand of the Natural Killer Cell Receptor NKG2D
- (2011) A. Heinemann et al. CANCER RESEARCH
- MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins
- (2011) Kasey C. Vickers et al. NATURE CELL BIOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth
- (2011) K L Streicher et al. ONCOGENE
- The widespread regulation of microRNA biogenesis, function and decay
- (2010) Jacek Krol et al. NATURE REVIEWS GENETICS
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- miRNA Expression Profiling in Melanocytes and Melanoma Cell Lines Reveals miRNAs Associated with Formation and Progression of Malignant Melanoma
- (2009) Daniel W. Mueller et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1
- (2009) R. Ueda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Circulating microRNAs as stable blood-based markers for cancer detection
- (2008) P. S. Mitchell et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now